Roger Kockelbergh
A5019263397- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Urological Disorders and Treatments
- Hormonal and reproductive studies
- Global Cancer Incidence and Screening
- Health Systems, Economic Evaluations, Quality of Life
- Angiogenesis and VEGF in Cancer
- Cancer survivorship and care
- Statistical Methods in Clinical Trials
- Estrogen and related hormone effects
- Renal and related cancers
- Multiple and Secondary Primary Cancers
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Screening and Detection
- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- Organ Donation and Transplantation
- COVID-19 and healthcare impacts
- Carcinogens and Genotoxicity Assessment
- Cancer, Hypoxia, and Metabolism
- Ureteral procedures and complications
- Patient-Provider Communication in Healthcare
University of Leicester
2003-2024
University Hospitals of Leicester NHS Trust
2015-2024
Cardiff University
2023
Action Cancer
2019-2022
Leicester General Hospital
1997-2020
King's College London
2012
University of Newcastle Australia
2012
Newcastle University
2012
Ollscoil na Gaillimhe – University of Galway
2012
University Hospitals Coventry and Warwickshire NHS Trust
2012
The comparative effectiveness of treatments for prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertain.
Robust data on patient-reported outcome measures comparing treatments for clinically localized prostate cancer are lacking. We investigated the effects of active monitoring, radical prostatectomy, and radiotherapy with hormones outcomes.
Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer was diagnosed 2664 men. Of these men, 1643 were enrolled trial to evaluate effectiveness treatments, with 545 randomly assigned receive active monitoring, 553 undergo prostatectomy, radiotherapy.
BackgroundUrothelial carcinomas of the upper urinary tract (UTUCs) are rare, with poorer stage-for-stage prognosis than urothelial bladder. No international consensus exists on benefit adjuvant chemotherapy for patients UTUCs after nephroureterectomy curative intent. The POUT (Peri-Operative versus sUrveillance in Tract cancer) trial aimed to assess efficacy systemic platinum-based UTUCs.MethodsWe did a phase 3, open-label, randomised controlled at 71 hospitals UK. We recruited UTUC staged...
BackgroundLong-term patient-reported outcomes are needed to inform treatment decisions for localized prostate cancer.MethodsPatient-reported of 1643 randomly assigned participants in the ProtecT (Prostate Testing Cancer and Treatment) trial were evaluated assess functional quality-of-life impacts prostatectomy, radiotherapy with neoadjuvant androgen deprivation, active monitoring. This article focuses on from 7 12 years using mixed effects linear logistic models.ResultsResponse rates...
The ProtecT trial reported intention-to-treat analysis of men with localised prostate cancer (PCa) randomly allocated to active monitoring (AM), radical prostatectomy, and external beam radiotherapy. To determine report outcomes according treatment received in randomised choice cohorts. This study focuses on secondary care. Men clinically at one nine UK centres were invited participate the comparing AM, Two cohorts included 1643 who agreed be randomised; 997 declined randomisation chose...
To investigate the functional and quality of life (QoL) outcomes treatments for localised prostate cancer inform treatment decision-making.Men aged 50-69 years diagnosed with by prostate-specific antigen testing biopsies at nine UK centres in Prostate Testing Cancer Treatment (ProtecT) trial were randomised to, or chose one of, three treatments. Of 2565 participants, 1135 men received active monitoring (AM), 750 a radical prostatectomy (RP), 603 external-beam radiotherapy (EBRT) concurrent...
Luteinising-hormone-releasing-hormone agonists (LHRHa) to treat prostate cancer are associated with long-term toxic effects, including osteoporosis. Use of parenteral oestrogen could avoid the complications LHRHa and thromboembolic oral oestrogen.In this multicentre, open-label, randomised, phase 2 trial, we enrolled men locally advanced or metastatic scheduled start indefinite hormone therapy. Randomisation was by minimisation, in a 2:1 ratio, four self-administered patches (100 μg per 24...
407 Background: The role of post nephro-ureterectomy (NU) treatment for UTUC is unclear. POUT (CRUK/11/027; NCT01993979) addresses whether adjuvant chemotherapy improves disease free survival (DFS) pts with histologically confirmed pT2-T4 N0-3 M0 UTUC. Methods: Pts (max n = 345) ≤90 days NU were randomised (1:1) to 4 cycles gemcitabine-cisplatin (gemcitabine-carboplatin if GFR 30-49ml/min) or surveillance subsequent required. had 6 monthly cross sectional imaging and cystoscopy the first 2...
We conducted a multicenter randomized trial in the United Kingdom to determine efficacy of radical radiotherapy reducing incidence progression pT1G3 transitional cell carcinoma bladder muscle invasive disease and subsequent fatality.Patients with new diagnosis NXM0 unifocal no situ (group 1), or multifocal and/or 2) were eligible for trial. Patients group 1 between observation bladder, 2 intravesical therapy radiotherapy.From September 1991 February 2003 total 210 patients from 37 centers...
Background Prostate cancer is the most common among men in UK. Prostate-specific antigen testing followed by biopsy leads to overdetection, overtreatment as well undertreatment of disease. Evidence treatment effectiveness has lacked because paucity randomised controlled trials comparing conventional treatments. Objectives To evaluate treatments for localised prostate (active monitoring, radical prostatectomy and radiotherapy) aged 50–69 years. Design A prospective, multicentre...
Early detection and treatment of asymptomatic men with advanced high-risk prostate cancer (PCa) may improve survival rates. To determine outcomes for diagnosed PCa following prostate-specific antigen (PSA) testing who were excluded from the ProtecT randomised trial. Mortality was compared 492 followed up a median 7.4 yr to contemporaneous cohort UK Anglia Cancer Network (ACN) matched subset ACN. PCa-specific all-cause mortality using Kaplan-Meier analysis Cox's proportional hazards...
In the UK, two main treatments of invasive bladder cancer are radiotherapy or cystectomy. However, approximately 50% patients undergoing fail to respond. If tumour radiosensitivity could be predicted in advance, it may possible improve control rates significantly by selecting for those whose tumours radiosensitive. Additionally, who would benefit from surgery identified earlier. The alkaline comet assay (ACA) is a sensitive method detection DNA strand break damage cells. present study, using...
OBJECTIVE To assess the hormonal effects of Fem7® (Merck, KGaA, Darmstadt, Germany) 100 µg transdermal oestrogen patches on men undergoing first‐line androgen‐deprivation therapy for prostate cancer. PATIENTS AND METHODS PATCH is a multicentre, randomized, phase II trial with locally advanced or metastatic cancer, comparing luteinizing hormone‐releasing hormone agonist patches. dosing schedule patches, as this was first time that brand patch had been used in men, and to reassure patients...
<h2>Abstract</h2><h3>Objectives</h3> To explore how the concept of randomization is described by clinicians and understood patients in randomized controlled trials (RCTs) it contributes to patient understanding recruitment. <h3>Study Design Setting</h3> Qualitative analysis 73 audio recordings recruitment consultations from five, multicenter, UK-based RCTs with identified or anticipated difficulties. <h3>Results</h3> One 10 appointments did not include any mention randomization. Most...
Androgen deprivation therapy (ADT), usually achieved with luteinising hormone releasing analogues (LHRHa), is central to prostate cancer management. LHRHa reduce both testosterone and oestrogen are associated significant long-term toxicity. Previous use of oral oestrogens as ADT was curtailed because cardiovascular Transdermal (tE2) patches a potential alternative ADT, supressing without the oestrogen-depletion toxicities (osteoporosis, hot flushes, metabolic abnormalities) avoiding...
Bladder cancer patients suffer significant treatment failure, including high rates of recurrence and poor outcomes for advanced disease. If mechanisms to improve tumour cell sensitivity could be identified and/or if response predicted, it should possible local-control survival. Previously, we have shown that radiation-induced DNA damage, measured by alkaline Comet assay (ACA), correlates bladder radiosensitivity in vitro. In this study first show modified-ACA measures cisplatin...
Abstract Introduction Bladder cancer is one of the most common cancers worldwide and can be managed with a range approaches, including conservative, medical surgical therapies. Treatment may associated considerable morbidity, but despite this, little data exist to reflect patients' subsequent experience. This study aims evaluate experiences bladder care by linking from national experience survey routinely collected National Health Service (NHS) sources. considers patient perspectives makes...